The government has today (1 December 2025) announced that it will increase the thresholds NICE uses in evaluations of new medicines to decide which are cost-effective for use in the NHS.

Final guidance published today (Thursday 4 December 2025) conditionally recommends seven digital technologies that can support cardiac rehabilitation for adults with cardiovascular disease in the NHS.

Glofitamab with gemcitabine and oxaliplatin for treating relapsed or refractory diffuse large B-cell lymphoma TA1113 3 December 2025 3 December 2025 Talquetamab for treating relapsed and refractory ...

Menotrophin prefilled pen for treating anovulation or during controlled ovarian hyperstimulation [TSID12290] Medicines evaluation Not selected 12 December 2025 Cyclosporin eye drops for treating ...

People with a rare and aggressive blood cancer will benefit from a potentially life saving treatment, following NICE’s recommendation of a CAR-T (chimeric antigen receptor T-cell) treatment developed ...

There is a simple discount patient access scheme for talquetamab. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...

There is a simple discount patient access scheme for glofitamab. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...

This guideline covers recognising, assessing and treating post-traumatic stress disorder (PTSD) in children, young people and adults. It aims to improve quality of life by reducing symptoms of PTSD ...

This guideline has been updated and replaced by NICE COVID-19 rapid guideline NG191.

This guidance has been updated and replaced by NICE technology appraisal guidance on pembrolizumab with pemetrexed and platinum chemotherapy for untreated ...

Decisions about updating our guidance are made by NICE’s prioritisation board. For more information on the principles and process, see NICE-wide topic prioritisation: the manual. For information about ...

This guideline covers the care of pregnant women and pregnant trans and non-binary people and their babies during labour and immediately after birth. It focuses on women and pregnant people who give ...